



(51) International Patent Classification:

C07K 16/28 (2006.01) *A61P 25/00* (2006.01)
C12N 15/13 (2006.01) *A61P 25/08* (2006.01)
A61K 39/395 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:

PCT/CN2025/081169

(22) International Filing Date:

07 March 2025 (07.03.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2024/080726
08 March 2024 (08.03.2024) CN

(71) Applicant: **SUNMED THERAPEUTIC LIMITED**
[CN/CN]; Unit 1507c 15/F Eastcore 398 Kwun Tong Road
Kwun Tong Kowloon, Hong Kong (CN).

(72) Inventor: **SUN, Dongxu**; Room 612, Building No.1 Shen-
zhen Institute Of Advanced Technology, No. 299, Huimao
Road, Guangming District, Shenzhen, Guangdong 518107
(CN).


(74) Agent: **UNITALEN ATTORNEYS AT LAW CO., LTD.**;
7th Floor, Scitech Place No. 22, Jian Guo Men Wai Ave.,
Chaoyang District, Beijing 100004 (CN).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-GALECTIN 3 ANTIBODIES AND THEIR USE IN EPILEPSY AND RELATED DISEASES

[Fig. 1]



(57) Abstract: Provided herein are antibodies that target Galectin-3. Such antibodies are used in methods of treating epilepsy and related neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).

[Continued on next page]

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*